Diabetes Type 2 Clinical Trial
Official title:
Personalized Nutrition for Diabetes Type 2
The study will investigate the effect of personalized diet on blood glucose control in
individuals with diabetes as compared with ADA diet.
The primary objective is to test whether personalized diets based on DayTwo's algorithm can
improve glycemic control and metabolic health compared to standard ADA acceptable dietary
approach for diabetes at the end of a 3-month intervention period.
The prevalence of diabetes type 2 estimated to 628 Million people in the world by 2045 and
was announced by the International Diabetes Federation (IDF) as one of the biggest epidemics
in the history. Complications of diabetics Type 2 can range from high blood sugar include
heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure,
and poor blood flow in the limbs which may lead to amputations. It is also linked to other
manifestations, collectively termed the metabolic syndrome, including obesity, hypertension,
non-alcoholic fatty liver disease, hypertriglyceridemia and cardiovascular disease .
As blood glucose levels are mainly affected by food consumption, the growing number of blood
glucose abnormalities is likely attributable to nutrition. Indeed, dietary and lifestyle
changes normalize blood glucose levels in 55% -80% of the cases. Therefore, maintaining
normal blood glucose levels is critical for preventing diabetes and its metabolic
complications.
Currently, there are no effective methods for predicting the postprandial glycemic response
(PPGR) of people to food. The current practice of using the meal carbohydrate content is a
poor predictor of the PPGR and has limited efficacy. The glycemic index (GI), which
quantifies PPGR to consumption of a single tested food type, and the derived glycemic load
have limited applicability in assessing the PPGR to real-life meals consisting of arbitrary
food combinations and varying quantities, consumed at different times of the day, and at
different proximity to physical activity and other meals. Indeed, studies examining the
effect of diets with a low glycemic index on TIIDM risk, weight loss, and cardiovascular risk
factors yielded mixed results . The limited success of GI measure is probably due to the fact
that it is a general index, which does not take into consideration the large variation
between individuals in their glycemic response to food. It can be concluded, therefore, that
in order to control glycemic response of an individual, we should build a personally tailored
diet which takes into account various factors.
Although genetic factors influence the levels of fasting blood glucose and glycemic response
to food, these factors only explain approximately 10% of the variance in the population.
Supporting this claim is the fact that the number of people with diabetes is increasing in
recent years regardless of patients' genetic background. In contrast, environmental factors
such as the composition of the intestinal bacteria and their metabolic activity may affect
the glycemic response. The entire bacteria population in the digestive tract (microbiome)
consist of ~1,000 species with a genetic repertoire of ~3 million different genes. The
microbiome is directly affected by our diet and directly affect the body's response to food.
This special relationship between the host and the intestinal flora is reflected by the
composition of bacteria unique to type 2 diabetes and in the significant changes in the
bacteria composition upon transition from a diet rich in fiber to a "Western" diet rich in
simple sugars.
Recently, DayTwo developed a highly accurate algorithm for predicting the personalized
glucose response to food for each person based on the PNP Study conducted by the Weizmann
Institute. The algorithm's predictions are based on many personal measurements, including
blood tests, personal lifestyle and gut bacteria. In a small-scale pilot study that was
conducted by the Weizmann Institute using the algorithm, the researchers personally tailored
dietary interventions to healthy and prediabetic people, which resulted in significantly
improved PPGRs accompanied by consistent alterations to the gut microbiota. These findings
led to hypothesize that tailoring personalized diets based on PPGRs predictions may achieve
better outcomes in terms of controlling blood glucose levels and its metabolic consequences
relative to the current standard nutritional therapy for diabetes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Active, not recruiting |
NCT04954313 -
Baseline Oral Health Study: UnCoVer the Connections to General Health
|
Phase 4 | |
Not yet recruiting |
NCT06437782 -
Exploration of Health Literacy in Diabetes in Reunion Island and France
|
||
Completed |
NCT01354925 -
Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan
|
Phase 4 | |
Completed |
NCT01206725 -
Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction
|
N/A | |
Completed |
NCT00997282 -
A Study of OPC-262 in Patients With Type 2 Diabetes
|
Phase 2/Phase 3 | |
Completed |
NCT00637546 -
Gait and Balance of Diabetes Type 2 Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00464880 -
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02057497 -
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
|
N/A | |
Active, not recruiting |
NCT05014204 -
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
|
N/A | |
Completed |
NCT04276051 -
Cryovagotomy Diabetes Trial
|
N/A | |
Completed |
NCT02569684 -
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
Terminated |
NCT01722474 -
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
|
N/A | |
Completed |
NCT00977262 -
Postprandial Inflammation and Fatty Acids
|
N/A | |
Completed |
NCT00518427 -
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
|
Phase 4 | |
Recruiting |
NCT05378620 -
Project Dulce for Filipino-Americans With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT03834207 -
A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy
|
N/A | |
Active, not recruiting |
NCT05228067 -
Enhancing Brain Health by tDCS in Persons With Overweight and Obesity
|
N/A | |
Active, not recruiting |
NCT05689684 -
Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes
|
N/A |